Cargando…

The Role of in silico Research in Developing Nanoparticle-Based Therapeutics

Nanoparticles (NPs) hold great potential as therapeutics, particularly in the realm of drug delivery. They are effective at functional cargo delivery and offer a great degree of amenability that can be used to offset toxic side effects or to target drugs to specific regions in the body. However, the...

Descripción completa

Detalles Bibliográficos
Autores principales: Jayasinghe, Migara Kavishka, Lee, Chang Yu, Tran, Trinh T. T., Tan, Rachel, Chew, Sarah Min, Yeo, Brendon Zhi Jie, Loh, Wen Xiu, Pirisinu, Marco, Le, Minh T. N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8965754/
https://www.ncbi.nlm.nih.gov/pubmed/35373184
http://dx.doi.org/10.3389/fdgth.2022.838590
_version_ 1784678501888032768
author Jayasinghe, Migara Kavishka
Lee, Chang Yu
Tran, Trinh T. T.
Tan, Rachel
Chew, Sarah Min
Yeo, Brendon Zhi Jie
Loh, Wen Xiu
Pirisinu, Marco
Le, Minh T. N.
author_facet Jayasinghe, Migara Kavishka
Lee, Chang Yu
Tran, Trinh T. T.
Tan, Rachel
Chew, Sarah Min
Yeo, Brendon Zhi Jie
Loh, Wen Xiu
Pirisinu, Marco
Le, Minh T. N.
author_sort Jayasinghe, Migara Kavishka
collection PubMed
description Nanoparticles (NPs) hold great potential as therapeutics, particularly in the realm of drug delivery. They are effective at functional cargo delivery and offer a great degree of amenability that can be used to offset toxic side effects or to target drugs to specific regions in the body. However, there are many challenges associated with the development of NP-based drug formulations that hamper their successful clinical translation. Arguably, the most significant barrier in the way of efficacious NP-based drug delivery systems is the tedious and time-consuming nature of NP formulation—a process that needs to account for downstream effects, such as the onset of potential toxicity or immunogenicity, in vivo biodistribution and overall pharmacokinetic profiles, all while maintaining desirable therapeutic outcomes. Computational and AI-based approaches have shown promise in alleviating some of these restrictions. Via predictive modeling and deep learning, in silico approaches have shown the ability to accurately model NP-membrane interactions and cellular uptake based on minimal data, such as the physicochemical characteristics of a given NP. More importantly, machine learning allows computational models to predict how specific changes could be made to the physicochemical characteristics of a NP to improve functional aspects, such as drug retention or endocytosis. On a larger scale, they are also able to predict the in vivo pharmacokinetics of NP-encapsulated drugs, predicting aspects such as circulatory half-life, toxicity, and biodistribution. However, the convergence of nanomedicine and computational approaches is still in its infancy and limited in its applicability. The interactions between NPs, the encapsulated drug and the body form an intricate network of interactions that cannot be modeled with absolute certainty. Despite this, rapid advancements in the area promise to deliver increasingly powerful tools capable of accelerating the development of advanced nanoscale therapeutics. Here, we describe computational approaches that have been utilized in the field of nanomedicine, focusing on approaches for NP design and engineering.
format Online
Article
Text
id pubmed-8965754
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89657542022-03-31 The Role of in silico Research in Developing Nanoparticle-Based Therapeutics Jayasinghe, Migara Kavishka Lee, Chang Yu Tran, Trinh T. T. Tan, Rachel Chew, Sarah Min Yeo, Brendon Zhi Jie Loh, Wen Xiu Pirisinu, Marco Le, Minh T. N. Front Digit Health Digital Health Nanoparticles (NPs) hold great potential as therapeutics, particularly in the realm of drug delivery. They are effective at functional cargo delivery and offer a great degree of amenability that can be used to offset toxic side effects or to target drugs to specific regions in the body. However, there are many challenges associated with the development of NP-based drug formulations that hamper their successful clinical translation. Arguably, the most significant barrier in the way of efficacious NP-based drug delivery systems is the tedious and time-consuming nature of NP formulation—a process that needs to account for downstream effects, such as the onset of potential toxicity or immunogenicity, in vivo biodistribution and overall pharmacokinetic profiles, all while maintaining desirable therapeutic outcomes. Computational and AI-based approaches have shown promise in alleviating some of these restrictions. Via predictive modeling and deep learning, in silico approaches have shown the ability to accurately model NP-membrane interactions and cellular uptake based on minimal data, such as the physicochemical characteristics of a given NP. More importantly, machine learning allows computational models to predict how specific changes could be made to the physicochemical characteristics of a NP to improve functional aspects, such as drug retention or endocytosis. On a larger scale, they are also able to predict the in vivo pharmacokinetics of NP-encapsulated drugs, predicting aspects such as circulatory half-life, toxicity, and biodistribution. However, the convergence of nanomedicine and computational approaches is still in its infancy and limited in its applicability. The interactions between NPs, the encapsulated drug and the body form an intricate network of interactions that cannot be modeled with absolute certainty. Despite this, rapid advancements in the area promise to deliver increasingly powerful tools capable of accelerating the development of advanced nanoscale therapeutics. Here, we describe computational approaches that have been utilized in the field of nanomedicine, focusing on approaches for NP design and engineering. Frontiers Media S.A. 2022-03-16 /pmc/articles/PMC8965754/ /pubmed/35373184 http://dx.doi.org/10.3389/fdgth.2022.838590 Text en Copyright © 2022 Jayasinghe, Lee, Tran, Tan, Chew, Yeo, Loh, Pirisinu and Le. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Digital Health
Jayasinghe, Migara Kavishka
Lee, Chang Yu
Tran, Trinh T. T.
Tan, Rachel
Chew, Sarah Min
Yeo, Brendon Zhi Jie
Loh, Wen Xiu
Pirisinu, Marco
Le, Minh T. N.
The Role of in silico Research in Developing Nanoparticle-Based Therapeutics
title The Role of in silico Research in Developing Nanoparticle-Based Therapeutics
title_full The Role of in silico Research in Developing Nanoparticle-Based Therapeutics
title_fullStr The Role of in silico Research in Developing Nanoparticle-Based Therapeutics
title_full_unstemmed The Role of in silico Research in Developing Nanoparticle-Based Therapeutics
title_short The Role of in silico Research in Developing Nanoparticle-Based Therapeutics
title_sort role of in silico research in developing nanoparticle-based therapeutics
topic Digital Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8965754/
https://www.ncbi.nlm.nih.gov/pubmed/35373184
http://dx.doi.org/10.3389/fdgth.2022.838590
work_keys_str_mv AT jayasinghemigarakavishka theroleofinsilicoresearchindevelopingnanoparticlebasedtherapeutics
AT leechangyu theroleofinsilicoresearchindevelopingnanoparticlebasedtherapeutics
AT trantrinhtt theroleofinsilicoresearchindevelopingnanoparticlebasedtherapeutics
AT tanrachel theroleofinsilicoresearchindevelopingnanoparticlebasedtherapeutics
AT chewsarahmin theroleofinsilicoresearchindevelopingnanoparticlebasedtherapeutics
AT yeobrendonzhijie theroleofinsilicoresearchindevelopingnanoparticlebasedtherapeutics
AT lohwenxiu theroleofinsilicoresearchindevelopingnanoparticlebasedtherapeutics
AT pirisinumarco theroleofinsilicoresearchindevelopingnanoparticlebasedtherapeutics
AT leminhtn theroleofinsilicoresearchindevelopingnanoparticlebasedtherapeutics
AT jayasinghemigarakavishka roleofinsilicoresearchindevelopingnanoparticlebasedtherapeutics
AT leechangyu roleofinsilicoresearchindevelopingnanoparticlebasedtherapeutics
AT trantrinhtt roleofinsilicoresearchindevelopingnanoparticlebasedtherapeutics
AT tanrachel roleofinsilicoresearchindevelopingnanoparticlebasedtherapeutics
AT chewsarahmin roleofinsilicoresearchindevelopingnanoparticlebasedtherapeutics
AT yeobrendonzhijie roleofinsilicoresearchindevelopingnanoparticlebasedtherapeutics
AT lohwenxiu roleofinsilicoresearchindevelopingnanoparticlebasedtherapeutics
AT pirisinumarco roleofinsilicoresearchindevelopingnanoparticlebasedtherapeutics
AT leminhtn roleofinsilicoresearchindevelopingnanoparticlebasedtherapeutics